UY32131A - Compuestos de anillo fusionado y uso de los mismos - Google Patents

Compuestos de anillo fusionado y uso de los mismos

Info

Publication number
UY32131A
UY32131A UY0001032131A UY32131A UY32131A UY 32131 A UY32131 A UY 32131A UY 0001032131 A UY0001032131 A UY 0001032131A UY 32131 A UY32131 A UY 32131A UY 32131 A UY32131 A UY 32131A
Authority
UY
Uruguay
Prior art keywords
fusioned
same
ring compounds
present
glucokinase activator
Prior art date
Application number
UY0001032131A
Other languages
English (en)
Inventor
Yasuma Tsuneo
Takakura Nobuyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32131A publication Critical patent/UY32131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención apunta a proveer un activador de glucoquinasa útil como agente farmacéutico tal como un agente para la profilaxis o el tratamiento de diabetes, obesidad y similares. La presente invención provee un activador de glucoquinasa que contiene un compuesto representado por la fórmula (I) : donde cada símbolo se define en la memoria descriptiva, o una sal del mismo o una prodroga del mismo.
UY0001032131A 2008-04-10 2009-09-21 Compuestos de anillo fusionado y uso de los mismos UY32131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10
PCT/JP2009/057625 WO2009125873A1 (en) 2008-04-10 2009-04-09 Fused ring compounds and use thereof

Publications (1)

Publication Number Publication Date
UY32131A true UY32131A (es) 2010-11-30

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032131A UY32131A (es) 2008-04-10 2009-09-21 Compuestos de anillo fusionado y uso de los mismos

Country Status (35)

Country Link
US (1) US8673942B2 (es)
EP (1) EP2276760B1 (es)
JP (1) JP5528348B2 (es)
KR (1) KR20110002472A (es)
CN (1) CN102056924B (es)
AR (1) AR073609A1 (es)
AU (1) AU2009234666B2 (es)
BR (1) BRPI0910912A2 (es)
CA (1) CA2720686A1 (es)
CO (1) CO6321240A2 (es)
CR (1) CR11730A (es)
CY (1) CY1115247T1 (es)
DK (1) DK2276760T3 (es)
DO (1) DOP2010000301A (es)
EA (1) EA019640B1 (es)
EC (1) ECSP10010602A (es)
ES (1) ES2476265T3 (es)
GE (1) GEP20135846B (es)
HK (1) HK1152932A1 (es)
HR (1) HRP20140588T1 (es)
IL (1) IL208463A (es)
MA (1) MA32283B1 (es)
ME (1) ME01887B (es)
MX (1) MX2010011138A (es)
MY (1) MY152475A (es)
NZ (1) NZ588562A (es)
PE (1) PE20100734A1 (es)
PL (1) PL2276760T3 (es)
PT (1) PT2276760E (es)
RS (1) RS53378B (es)
SI (1) SI2276760T1 (es)
UA (1) UA104422C2 (es)
UY (1) UY32131A (es)
WO (1) WO2009125873A1 (es)
ZA (1) ZA201007682B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
EP2931734B1 (en) * 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015301A1 (en) 1991-03-01 1992-09-17 H. Lundbeck A/S Treatment of hypertension and peripheral vascular diseases
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
EA008769B1 (ru) 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
CN101801965B (zh) * 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
RU2450001C2 (ru) 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
US20100291533A1 (en) 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE

Also Published As

Publication number Publication date
BRPI0910912A2 (pt) 2015-08-11
EA201071180A1 (ru) 2011-04-29
CO6321240A2 (es) 2011-09-20
SI2276760T1 (sl) 2014-05-30
US8673942B2 (en) 2014-03-18
EA019640B1 (ru) 2014-05-30
CA2720686A1 (en) 2009-10-15
HRP20140588T1 (hr) 2014-08-01
CN102056924A (zh) 2011-05-11
PT2276760E (pt) 2014-05-28
GEP20135846B (en) 2013-06-10
CN102056924B (zh) 2014-05-21
ES2476265T3 (es) 2014-07-14
ZA201007682B (en) 2011-12-28
JP2011516403A (ja) 2011-05-26
EP2276760B1 (en) 2014-04-09
KR20110002472A (ko) 2011-01-07
IL208463A0 (en) 2010-12-30
CR11730A (es) 2010-12-08
WO2009125873A1 (en) 2009-10-15
PE20100734A1 (es) 2010-11-18
NZ588562A (en) 2012-07-27
AR073609A1 (es) 2010-11-17
PL2276760T3 (pl) 2014-09-30
IL208463A (en) 2015-07-30
MA32283B1 (fr) 2011-05-02
EP2276760A1 (en) 2011-01-26
DK2276760T3 (da) 2014-05-26
CY1115247T1 (el) 2017-01-04
AU2009234666B2 (en) 2014-02-20
ECSP10010602A (es) 2011-03-31
DOP2010000301A (es) 2010-12-31
MX2010011138A (es) 2010-11-12
ME01887B (me) 2014-12-20
JP5528348B2 (ja) 2014-06-25
MY152475A (en) 2014-10-15
HK1152932A1 (en) 2012-03-16
US20110098297A1 (en) 2011-04-28
UA104422C2 (uk) 2014-02-10
RS53378B (en) 2014-10-31
AU2009234666A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
ECSP099330A (es) Compuesto de indol
CR10564A (es) Compuestos cíclicos fusionados
DOP2010000267A (es) Compuesto heterociclico
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
ECSP13012719A (es) Compuesto bicíclico
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CU20110212A7 (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
ECSP11010880A (es) Compuestos orgánicos
ECSP12011573A (es) Compuestos tetracíclicos
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
ECSP11011558A (es) Nuevos compuestos químicos.
CO6640253A2 (es) Derivados de compuesto biciclico y su uso como inhibidores de acc
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
CO6382113A2 (es) Compuestos quimicos
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
BR112017005241A2 (pt) composto, e, composição farmacêutica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181114